Evidence map›Paper›PMID 33323006›Full record

ArticlemAbs

Monoclonal antibody 2C5 specifically targets neutrophil extracellular traps.

Livia P Mendes, Kobra Rostamizadeh, Kandace Gollomp, Jacob W Myerson, Oscar A Marcos-Contreras, Marco Zamora, Ed Luther, Jacob S Brenner, Nina Filipczak, Xiang Li and 1 more

Open access · goldAbstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 5 countries.

Livia P MendesCenter for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University , Boston, MA, USA.
Kobra RostamizadehZanjan Pharmaceutical Nanotechnology Research Center, School of Pharmacy, Pharmaceutical Biomaterials Department, Zanjan University of Medical Sciences , Zanjan, Iran.
Kandace GollompDivision of Hematology, Children's Hospital of Philadelphia , Philadelphia, PA, USA.
Jacob W MyersonDepartment of Systems Pharmacology and Translational Therapeutics, University of Philadelphia , Philadelphia, PA, USA.
Oscar A Marcos-ContrerasDepartment of Systems Pharmacology and Translational Therapeutics, University of Philadelphia , Philadelphia, PA, USA.
Marco ZamoraDepartment of Systems Pharmacology and Translational Therapeutics, University of Philadelphia , Philadelphia, PA, USA.
Ed LutherDepartment of Pharmaceutical Sciences, Northeastern University , Boston, MA, USA.
Jacob S BrennerDepartment of Systems Pharmacology and Translational Therapeutics, University of Philadelphia , Philadelphia, PA, USA.
Nina FilipczakCenter for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University , Boston, MA, USA.
Xiang LiCenter for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University , Boston, MA, USA.
Vladimir P TorchilinCenter for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University , Boston, MA, USA.
Northeastern University · USTranslational Therapeutics (United States) · USChildren's Hospital of Philadelphia · USJiangxi University of Traditional Chinese Medicine · CNZanjan University of Medical Sciences · IR

Funding

Nanoscale drug carriers for the treatment of Acute Respiratory Distress Syndrome (ARDS).F31HL154662 · NHLBI · DREXEL UNIVERSITY · PI ZAMORA, MARCO E · 2020 to 2023
$186k
NHLBI NIH HHS F31 HL154662
6 · The paper itself

Abstract

Neutrophils can release DNA and granular cytoplasmic proteins that form smooth filaments of stacked nucleosomes (NS). These structures, called neutrophil extracellular traps (NETs), are involved in multiple pathological processes, and NET formation and removal are clinically significant. The monoclonal antibody 2C5 has strong specificity toward intact NS but not to individual NS components, indicating that 2C5 could potentially target NS in NETs. In this study, NETs were generated

Indexed as

Antibodies, Monoclonal, Murine-DerivedAntibody SpecificityExtracellular TrapsAnimalsHL-60 CellsHumansMiceMice, Inbred BALB CAntibodies, Monoclonal, Murine-Derived2C5active targetingmonoclonal antibodyNeutrophil extracellular traps

Identifiers

PMID33323006
PMCPMC7755171
OpenAlexW3110725461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.